P283 Patient-reported symptoms over a period of 14 days reliably predict endoscopic and histological disease activity in ulcerative colitis (UC)
ECCO'20 Vienna
2020
P284 Disentangling fibromyalgia from spondyloarthopathy in the patient with inflammatory bowel disease
ECCO'20 Vienna
2020
P285 Is faecal immunochemical test a suitable alternative to faecal calprotectin in children?
ECCO'20 Vienna
2020
P286 Rate of colectomy in ulcerative colitis: Results from a Spanish cohort with 15 years of follow-up
ECCO'20 Vienna
2020
P288 Gut barrier failure biomarkers in IBD: Is there anything new beyond „The Wall’?
ECCO'20 Vienna
2020
P289 Biological therapies and the trajectories of biopsychological factors in inflammatory bowel diseases
ECCO'20 Vienna
2020
P290 Long-term disease outcome of ulcerative colitis (UC) in South Ostrobothnia, Finland with a follow-up time of 25 years
ECCO'20 Vienna
2020
P291 Diagnostic utility of the neutrophil-platelet rate (NeuPla) as a marker of activity in patients with ulcerative colitis
ECCO'20 Vienna
2020
P292 Inflammatory bowel disease and their implications in Roma ethnicity: A preliminary study
ECCO'20 Vienna
2020
P293 Loss of response after first-line biologic therapy in patients with inflammatory bowel disease: practical approach and management
ECCO'20 Vienna
2020
P295 VALIDation of the IBD-Disk instrument for assessing disability in inflammatory bowel diseases in a population-based cohort: The VALIDate study
ECCO'20 Vienna
2020
P296 Quality of reporting of lesions detected at surveillance colonoscopy for IBD
ECCO'20 Vienna
2020
P298 Patient-reported outcomes: the ICHOM standard set for IBD in real-life practice helps quantify deficits in current care
ECCO'20 Vienna
2020
P300 Colectomy and health-related quality life in children with ulcerative colitis
ECCO'20 Vienna
2020